| Prosonix and University of Bath Win Royal Society of Chemistry Innovation Award |
| Prosonix Limited (Oxford, UK) and the University of Bath (Bath, UK) are delighted to announce that they have won the Royal Society of Chemistry’s 2006 Team Innovation Award for their novel particle engineering technology Solution, Atomisation and Crystallization by Sonication(SAXTM).
The Royal Society of Chemistry is Europe’s Largest Professional Organisation for Advancing the Chemical Sciences, and one of the worlds oldest and most prestigious scientific institutions. |
| |
|
 |
 |
| Bath and Prosonix Sign Agreement for SAX Technology |
| The University of Bath (Bath, UK) and Prosonix Limited (Oxford, UK) are delighted to announce the signing of an exclusive agreement for the development and commercialisation of the
University’s novel particle engineering technology Solution, Atomisation and Crystallization by Sonication (SAX). |
| |
|
|
|
| Prosonix Ltd Appoints John Burns As Development Project Engineer |
| Prosonix (Oxford UK) Experts in Sound ScienceTM and acknowledged world leaders in the commercialisation of added value ultrasonic process solutions have appointed Dr John Burns as Development Project Engineer. |
| |
|
|
|
| License Agreement for World Wide Exploitation of Technology |
| Prosonix Limited (Oxford, UK) announce the signing of a far reaching License Agreement for the commercial application of Prosonix’s proprietary C3 sonocrystallization technology at Alcoa’s alumina refineries worldwide. |
| |
|
|
|
| Prosonix and UCB Extend Co-Development Agreement |
| Prosonix Ltd (Oxford UK) and UCB SA (Braine l’Alleud, Belgium), are pleased to announce the extension of their Co-Development and Licensing Agreement for the utilization of Prosonix’ proprietary sonocrystallization technology across a range of its pharmaceutical products. |
| |
|
|
|
| Prosonix Launches New SAXTM Technology |
| Prosonix Limited (Oxford, UK) is delighted to announce an agreement with the University of Bath (Bath, UK) for the exclusive commercialisation of the University’s unique sonocrystallization particle engineering technology Solution Atomisation and Crystallization by Sonication (SAXTM). The agreement builds on 18 months of initial collaboration and technology evaluation between the parties. |
| |
|
|
|
| Prosonix Shortlisted for CPHI 2006 Innovation Award |
| Prosonix (Oxford UK) are delighted to announce that for the second year in succession, they have been short listed for
the CPhI Worldwide Innovation Award, for their new SAXTM particle engineering technology, which has been under
development in partnership with Dr Rob Price of the University of Bath (Bath, UK). This international peer recognition
of the potential of SAXTM (Solution Atomization and Sonocrystallization) follows on from their CPhI Worldwide 2005
Innovation Award Gold Medal success for CrystalGEMTM, and confirms Prosonix’s status as an acknowledged world
leader in the commercialisation of cutting edge technology in pharmaceutical ultrasonic process chemistry. |
| |
|
|
|
| Prosonix Appoints New Business Development Manager |
| Prosonix (Oxford UK) Experts in Sound ScienceTM and acknowledged world leaders in the commercialisation of added value ultrasonic process solutions have appointed Christian Jones as its new Business Development Manager. |
| |
|
|
|
| Prosonix Appoints New Chairman Designate |
| Prosonix (Oxford UK) are pleased to announce the appointment of Nigel Bell as their new Executive Chairman designate. The appointment will be formalised at Prosonix’ next Board meeting in October 2006. |
| |
|
|
|
| World First For C3 |
| Accentus C3 Technology (Harwell UK) have successfully commissioned the world’s first commercial scale C3
continuous Sonocrystallization system. |
| |
|
|
|
| C3 and Chiralabs Win Global Innovation Award |
| Accentus C3 Technology’s [Harwell, Oxon, UK] and Chiralabs [Kidlington, Oxon, UK] unique
CrystalGEMTM Predictive Crystallization Technology has won the Gold Award for
Innovation at this years CPhI 2005 Worldwide tradeshow in Madrid, beating 6 other major
international corporations in the process. |
| |
|
|
|
| Billion Dollar Backers for C3 |
| Accentus C3 Technology is set to benefit significantly following its acquisition by Coller Capital. Coller
completed a £40 million cash transaction on 30 September 2005 for 9 non-core portfolio businesses,
including C3, as part of a planned disposal program by AEA Technology plc. |
| |
|
|
|
| C3 Accentus and Aughinish Alumina Commisson World’s First Commercial Scale C3 Sonocrystallization System |
| Accentus Ltd (Harwell UK) and Aughinish Alumina Ltd (Askeaton, Ireland) a Glencore Company, announce the commissioning of the world’s first commercial scale C3 continuous Sonocrystallization system at Europe’s largest alumina production facility. |
| |
|
|
|
| C3 Launches New Protein Crystallization Process Development Service |
| Accentus C3 Technology has launched a new protein crystallization process development service that is specifically targeted towards the rapidly growing needs of the emergent biopharmaceutical industry. |
| |
|
|
|
| C3 Launches New Predictive Crystallization Technology At CPHI |
| Accentus C3 Technology launches today at CPHI a unique in-silico predictive crystallization capability that is set to revolutionise the way that the life science industry approaches crystallization problems. |
| |
|
|
|
| Accentus & HEL Work Together To Develop Novel C3 Sonocrystallization Mini Reactors
|
| Accentus Ltd (Harwell UK) and HEL are pleased to announce the their co-operation to develop a new range of novel high quality computer controlled sonocrystallization micro-reactors utilizing Accentus’ proprietary patented C3 Sonocrystallization Technology. |
| |
|
|
|
| Accentus & Aughinish Alumina Sign License Agreement For Commercialisation of C3 Sonocrystallization Technology |
| Accentus Ltd (Harwell UK) and Aughinish Alumina Ltd (Askeaton, Ireland) a Glencore Company, announce the signing of a License Agreement for the commercial application of Accentus’ proprietary C3 Sonocrystallization Technology to enhance the productivity of Europe’s largest alumina production facility. |
| |
|
|
|
| New Laboratories for C3 |
| In line with the rapid growth of the business over the last 12 months, Accentus C3 technology business has moved into new laboratories in Oxfordshire, UK. |
| |
|
|
|
| C3 Technology Delivers |
| Launched at CPHI 2002 in the Show Daily, Accentus C3 Technology for Complete Crystallization Control™ has made excellent commercial progress in the last 12 months. |
| |
|
|
|
| C3 Technology Appoints New Head of Process Development |
| Accentus C3 Technology business has appointed Dr Graham Ruecroft as Head of Process Development. This newly created role underpins the recent growth of the C3 business as confirms the acceptance of Accentus C3 proprietary ultrasonic technology as a key tool for Complete Crystallization Control™ by the chemical industry. |
| |
|
|
|
| NPL To Use Accentus C3 Ultrasonic Technology For Research into Cavitation Monitoring Techniques |
| The National Physical Laboratory (NPL, Teddington UK), the UK’s national standards laboratory, and Accentus, (Harwell UK) are pleased to announce that NPL are applying the Accentus patented C3 power ultrasonic reactor technology as part of a research programme whose objective is to investigate methods of characterising cavitation activity with high power applications. |
| |
|
|
|
| Accentus & CBC Co. Ltd. Sign Exclusive Marketing Agreement for C3 Ultrasonic Technology In Japan |
| The National Physical Laboratory (NPL, Teddington UK), the UK’s national standards laboratory, and Accentus, (Harwell UK) are pleased to announce that NPL are applying the Accentus patented C3 power ultrasonic reactor technology as part of a research programme whose objective is to investigate methods of characterising cavitation activity with high power applications. |
| |
|
|
|
|
